AZU-1: A Candidate Breast Tumor Suppressor and Biomarker for Tumor Progression
AUTOR(ES)
Chen, Huei-Mei
FONTE
The American Society for Cell Biology
RESUMO
To identify genes misregulated in the final stages of breast carcinogenesis, we performed differential display to compare the gene expression patterns of the human tumorigenic mammary epithelial cells, HMT-3522-T4-2, with those of their immediate premalignant progenitors, HMT-3522-S2. We identified a novel gene, called anti-zuai-1 (AZU-1), that was abundantly expressed in non- and premalignant cells and tissues but was appreciably reduced in breast tumor cell types and in primary tumors. The AZU-1 gene encodes an acidic 571-amino-acid protein containing at least two structurally distinct domains with potential protein-binding functions: an N-terminal serine and proline-rich domain with a predicted immunoglobulin-like fold and a C-terminal coiled-coil domain. In HMT-3522 cells, the bulk of AZU-1 protein resided in a detergent-extractable cytoplasmic pool and was present at much lower levels in tumorigenic T4-2 cells than in their nonmalignant counterparts. Reversion of the tumorigenic phenotype of T4-2 cells, by means described previously, was accompanied by the up-regulation of AZU-1. In addition, reexpression of AZU-1 in T4-2 cells, using viral vectors, was sufficient to reduce their malignant phenotype substantially, both in culture and in vivo. These results indicate that AZU-1 is a candidate breast tumor suppressor that may exert its effects by promoting correct tissue morphogenesis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=14852Documentos Relacionados
- DBC2, a candidate for a tumor suppressor gene involved in breast cancer
- Jade-1, a candidate renal tumor suppressor that promotes apoptosis
- ANX7, a candidate tumor suppressor gene for prostate cancer
- Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression?
- TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression